RS60250B1 - Humanizovana antihumana cd19 antitela i postupci primene - Google Patents

Humanizovana antihumana cd19 antitela i postupci primene

Info

Publication number
RS60250B1
RS60250B1 RS20200530A RSP20200530A RS60250B1 RS 60250 B1 RS60250 B1 RS 60250B1 RS 20200530 A RS20200530 A RS 20200530A RS P20200530 A RSP20200530 A RS P20200530A RS 60250 B1 RS60250 B1 RS 60250B1
Authority
RS
Serbia
Prior art keywords
antibodies
human
methods
humanized anti
humanized
Prior art date
Application number
RS20200530A
Other languages
English (en)
Inventor
Guy Georges
Ekkehard Moessner
Laurent Lariviere
Alexander Haas
Hubert Kettenberger
Koller Claudia Ferrara
Tilman Schlothauer
Michael Molhoj
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS60250B1 publication Critical patent/RS60250B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20200530A 2015-10-01 2016-09-30 Humanizovana antihumana cd19 antitela i postupci primene RS60250B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15187820 2015-10-01
PCT/EP2016/073412 WO2017055541A1 (en) 2015-10-01 2016-09-30 Humanized anti-human cd19 antibodies and methods of use
EP16775243.5A EP3356408B1 (en) 2015-10-01 2016-09-30 Humanized anti-human cd19 antibodies and methods of use

Publications (1)

Publication Number Publication Date
RS60250B1 true RS60250B1 (sr) 2020-06-30

Family

ID=54251433

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200530A RS60250B1 (sr) 2015-10-01 2016-09-30 Humanizovana antihumana cd19 antitela i postupci primene

Country Status (32)

Country Link
US (2) US11286300B2 (sr)
EP (2) EP3356408B1 (sr)
JP (2) JP6629437B2 (sr)
KR (1) KR20180056768A (sr)
CN (2) CN108137696B (sr)
AR (1) AR106188A1 (sr)
AU (2) AU2016333511B2 (sr)
BR (1) BR112018006579A2 (sr)
CA (1) CA3000562A1 (sr)
CL (1) CL2018000728A1 (sr)
CO (1) CO2018002265A2 (sr)
CR (1) CR20180141A (sr)
DK (1) DK3356408T3 (sr)
ES (1) ES2791989T3 (sr)
HK (1) HK1251585A1 (sr)
HR (1) HRP20200767T1 (sr)
HU (1) HUE049083T2 (sr)
IL (2) IL257679B (sr)
LT (1) LT3356408T (sr)
MA (2) MA43024B1 (sr)
MX (2) MX2018003410A (sr)
MY (1) MY185171A (sr)
PE (1) PE20181054A1 (sr)
PH (1) PH12018500708A1 (sr)
PL (1) PL3356408T3 (sr)
PT (1) PT3356408T (sr)
RS (1) RS60250B1 (sr)
RU (2) RU2020124153A (sr)
SI (1) SI3356408T1 (sr)
TW (2) TWI747842B (sr)
UA (1) UA125285C2 (sr)
WO (1) WO2017055541A1 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
PT3224275T (pt) 2014-11-14 2020-05-04 Hoffmann La Roche Moléculas de ligação ao antigénio que compreendem um ligando trimérico da família do tnf
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3913000A1 (en) * 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
BR112018069890A2 (pt) 2016-05-02 2019-02-05 Hoffmann La Roche polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
CN110088135A (zh) 2016-12-20 2019-08-02 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体和4-1bb(cd137)激动剂的组合疗法
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
EP3601345A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3703746A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Novel tnf family ligand trimer-containing antigen binding molecules
CR20210154A (es) 2018-10-01 2021-04-21 Hoffmann La Roche Moléculas de unión a antígeno bioespecíficas que comprenden el clon 212 anti-fap
KR20210108981A (ko) 2018-12-21 2021-09-03 에프. 호프만-라 로슈 아게 종양-표적화된 효현성 cd28 항원 결합 분자
JP2022515543A (ja) * 2018-12-30 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー 抗ウサギｃｄ１９抗体および使用方法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
PE20231080A1 (es) 2020-06-19 2023-07-17 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
RU2020122142A (ru) * 2020-07-03 2022-01-04 Петр Иванович Никитин Композиция и способ для улучшения эффективности и снижения побочных эффектов терапевтического агента, доставляемого к мишени с помощью магнитного поля
IL302569A (en) * 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156905B (it) 1977-04-18 1987-02-04 Hitachi Metals Ltd Articolo di ornamento atto ad essere fissato mediante un magnete permanente
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
SI1071752T1 (en) 1998-04-21 2003-12-31 Micromet Ag CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2385347C (en) 1999-10-04 2009-12-15 Medicago Inc. Method for regulating transcription of foreign genes
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
WO2002009573A2 (en) 2000-07-31 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of endometrial cancer
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2002034661A2 (en) 2000-10-19 2002-05-02 Henry Colombo Methods and apparatus for forming leak-proof coupling for beverage system
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
ATE356149T1 (de) 2001-11-14 2007-03-15 Affimed Therapeutics Ag Bispezifische antikörper gegen cd19 und cd16 und deren verwendung
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
AU2003277828B2 (en) 2002-10-29 2009-06-04 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
MXPA05006511A (es) 2002-12-16 2006-02-17 Genentech Inc Variantes de inmunoglobulina y sus usos.
EP1590372A2 (en) 2003-02-06 2005-11-02 Micromet AG Trimeric polypeptide construct to induce an enduring t cell response
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
ME03330B (me) 2003-11-05 2019-10-20 Roche Glycart Ag Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
EP1691833B1 (en) 2003-11-28 2010-03-03 Micromet AG Compositions comprising polypeptides
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
EP2357201B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2497829A1 (de) 2004-11-11 2012-09-12 TheraMAB LLC Superagonistische anti-CD-28 Antikörper
DOP2006000013A (es) * 2005-01-13 2006-07-15 Genentech Inc Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
TWI387602B (zh) 2005-02-07 2013-03-01 Roche Glycart Ag 與上皮生長因子受體（ｅｇｆｒ）結合之抗原結合分子，編碼該抗原結合分子之載體及其用途
JP5651285B2 (ja) 2005-02-15 2015-01-07 デューク ユニバーシティ 抗ｃｄ１９抗体および腫瘍学における使用
EP3153525A1 (en) 2005-03-23 2017-04-12 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2606081C (en) 2005-04-26 2013-09-17 Markus M. Heiss Combination of the application of antibodies for immunostimulation together with glucocorticoids
AU2013263717B2 (en) 2005-05-06 2016-05-19 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
AU2011265482B2 (en) 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
PT1877090E (pt) 2005-05-06 2014-04-15 Providence Health System Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
BRPI0610235B8 (pt) 2005-05-09 2021-05-25 Squibb & Sons Llc anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
EP1736482A1 (en) 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
ES2856451T3 (es) 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
CN105709237A (zh) 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CA2633756C (en) 2005-12-21 2015-11-24 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
KR101626988B1 (ko) 2007-04-03 2016-06-02 암젠 리서치 (뮌헨) 게엠베하 종간 특이적 이중특이적인 결합제들
CN101687915B8 (zh) 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
EP2009022A1 (en) 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
PL2310509T3 (pl) 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
CA2753158A1 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
EP2467165B1 (en) 2009-08-17 2015-01-07 Roche Glycart AG Targeted immunoconjugates
JP5744872B2 (ja) 2009-08-31 2015-07-08 ロシュ グリクアート アーゲー 親和性成熟ヒト化抗ｃｅａモノクローナル抗体
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2483310B1 (en) 2009-09-29 2014-08-13 Roche Glycart AG Bispecific death receptor agonistic antibodies
WO2011076683A1 (en) 2009-12-22 2011-06-30 Roche Glycart Ag Anti-her3 antibodies and uses thereof
PL2519543T3 (pl) 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
DK2542590T4 (da) 2010-03-05 2020-07-13 Univ Johns Hopkins Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8552024B2 (en) 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
AU2011288487B2 (en) 2010-08-13 2015-10-01 Roche Glycart Ag Anti-FAP antibodies and methods of use
CA2815266C (en) 2010-11-05 2023-09-05 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CN103429737B (zh) 2010-11-30 2020-07-14 中外制药株式会社 细胞毒诱导治疗剂
PL2673294T3 (pl) 2011-02-10 2016-11-30 Zmutowane polipeptydy interleukiny-2
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
WO2012130471A1 (en) 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
EP2714733B1 (en) 2011-05-21 2019-01-23 MacroGenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
TW201840336A (zh) 2011-08-01 2018-11-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
KR101886983B1 (ko) 2011-08-23 2018-08-08 로슈 글리카트 아게 2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
ES2857734T3 (es) 2011-08-23 2021-09-29 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AU2012298535A1 (en) 2011-08-23 2014-02-06 Roche Glycart Ag Bispecific antigen binding molecules
JP6159724B2 (ja) 2011-08-23 2017-07-05 ロシュ グリクアート アーゲー Ｔ細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
EP2578230A1 (en) 2011-10-04 2013-04-10 Trion Pharma Gmbh Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
BR112014018005B1 (pt) 2012-02-15 2021-06-29 F. Hoffmann-La Roche Ag Uso de um complexo não covalente imobilizado
EA035344B1 (ru) 2012-04-20 2020-05-29 Мерюс Н.В. Способ получения двух антител из одной клетки-хозяина
CA3212759A1 (en) 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
RU2650868C2 (ru) 2012-07-13 2018-04-17 Займворкс Инк. Биспецифические асимметричные гетеродимеры, содержащие анти-cd3 конструкции
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
RU2650788C2 (ru) 2012-08-07 2018-04-17 Роше Гликарт Аг Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией
EA201500208A1 (ru) 2012-08-08 2015-07-30 Роше Гликарт Аг Слитые белки, содержащие интерлейкин-10, и их применения
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6482471B2 (ja) 2012-12-21 2019-03-13 バイオアライアンス コマンディテール フェンノートシャップ 親水性の自壊性リンカー及びそのコンジュゲート
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
BR112015015824B1 (pt) 2013-02-26 2020-09-24 Roche Glycart Ag Molécula que se liga ao antígeno biespecífico que ativa células t, polinucleotídeo isolado ou pluralidade de polinucleotídeos, vetor, método para produzir uma molécula, composição farmacêutica e uso da molécula
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
AU2014236769B2 (en) 2013-03-15 2018-09-27 Amgen Inc. Heterodimeric bispecific antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
BR112015023498A2 (pt) 2013-03-15 2017-10-10 Glaxosmithkline Ip No 2 Ltd formulação para uma proteína terapêutica
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
ES2746136T3 (es) 2013-04-29 2020-03-04 Hoffmann La Roche Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
ES2686968T3 (es) 2013-05-06 2018-10-23 China Pharmaceutical University Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas
JP6618463B2 (ja) 2013-05-07 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三量体型抗原結合分子
US20160090416A1 (en) 2013-05-28 2016-03-31 Numab Ag Novel antibodies
CA2917886A1 (en) 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding constructs
EP3733710A1 (en) 2013-09-25 2020-11-04 Amgen, Inc Hetrodimeric v-c-fc-v-c antibody
NZ721309A (en) 2013-12-17 2019-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
KR102447878B1 (ko) 2013-12-17 2022-09-26 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
ES2864160T3 (es) 2014-01-06 2021-10-13 Hoffmann La Roche Módulos lanzadera de la barrera hematoencefálica monovalentes
CA2935665A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN103820393B (zh) 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
AU2015266797C1 (en) 2014-05-29 2019-04-04 Macrogenics, Inc. Tri-Specific Binding Molecules that specifically bind to multiple Cancer Antigens and methods of use thereof
EP3148573A4 (en) 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
FI3608337T3 (fi) 2014-08-04 2024-06-13 Hoffmann La Roche Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
RS59939B1 (sr) 2014-08-29 2020-03-31 Hoffmann La Roche Kombinovana terapija il-2 varijantom imunocitokina sa ciljanim delovanjem na tumor i antitelima na humani pd-l1
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
CA2962603A1 (en) 2014-09-26 2016-03-31 Macrogenics, Inc. Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016055593A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
PT3224275T (pt) * 2014-11-14 2020-05-04 Hoffmann La Roche Moléculas de ligação ao antigénio que compreendem um ligando trimérico da família do tnf
EA201791121A1 (ru) 2014-11-20 2018-04-30 Ф. Хоффманн-Ля Рош Аг Активирующие т-клетки биспецифические антигенсвязывающие молекулы против folri и cd3
LT3221357T (lt) 2014-11-20 2020-08-25 F. Hoffmann-La Roche Ag Bendros lengvosios grandinės ir naudojimo būdai
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN107660214B (zh) 2015-01-08 2022-02-08 根马布股份公司 针对cd3和cd20的双特异性抗体
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
PE20221262A1 (es) 2015-04-13 2022-08-16 Pfizer Anticuerpos terapeuticos y sus usos
EP3288981A1 (en) 2015-05-01 2018-03-07 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
FI3298030T3 (fi) 2015-05-18 2023-02-22 Pieris Pharmaceuticals Gmbh Syöpää ehkäisevä fuusiopolypeptidi
ES2957567T3 (es) 2015-06-16 2024-01-22 Hoffmann La Roche Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112018006350A2 (pt) 2015-10-02 2018-10-09 Hoffmann La Roche anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, formulação farmacêutica e uso do anticorpo
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
WO2017055318A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cd33xcd3 bispecific t cell activating antigen binding molecules
EP3913000A1 (en) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
US20170129962A1 (en) 2015-10-02 2017-05-11 Hoffmann-La Roche Inc. Multispecific antibodies
CN108602887B (zh) 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
RU2018116402A (ru) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
JP6768917B2 (ja) 2016-07-08 2020-10-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ラボラトリ試料を処理するための装置、ラボラトリオートメーションシステム、およびラボラトリ試料をピペット操作するための方法
CA3039430A1 (en) 2016-12-19 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
CN110088135A (zh) 2016-12-20 2019-08-02 豪夫迈·罗氏有限公司 抗cd20/抗cd3双特异性抗体和4-1bb(cd137)激动剂的组合疗法
WO2018127473A1 (en) 2017-01-03 2018-07-12 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
MA44670B1 (fr) 2017-03-17 2023-11-30 Sanofi Sa Protéines de liaison trispécifiques et/ou trivalentes
MX2019011656A (es) 2017-03-27 2019-12-02 Hoffmann La Roche Formatos mejorados de receptor de union a antigeno.
IL269531B1 (en) 2017-03-27 2024-06-01 Hoffmann La Roche Enhanced antigen binding receptors
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
KR20210108981A (ko) 2018-12-21 2021-09-03 에프. 호프만-라 로슈 아게 종양-표적화된 효현성 cd28 항원 결합 분자

Also Published As

Publication number Publication date
PE20181054A1 (es) 2018-07-03
RU2731156C1 (ru) 2020-08-31
KR20180056768A (ko) 2018-05-29
CN108137696B (zh) 2022-01-11
US20220204616A1 (en) 2022-06-30
US20180282409A1 (en) 2018-10-04
TWI747842B (zh) 2021-12-01
ES2791989T3 (es) 2020-11-06
MA55063A (fr) 2022-01-05
AR106188A1 (es) 2017-12-20
MX2018003410A (es) 2018-06-06
IL288457A (en) 2022-01-01
HK1251585A1 (zh) 2019-02-01
TWI800139B (zh) 2023-04-21
CR20180141A (es) 2018-04-24
CN114349862A (zh) 2022-04-15
PT3356408T (pt) 2020-05-15
JP2018529733A (ja) 2018-10-11
AU2022262918A1 (en) 2022-12-08
MY185171A (en) 2021-04-30
JP2020055842A (ja) 2020-04-09
CA3000562A1 (en) 2017-04-06
MX2021011167A (es) 2021-10-22
IL257679A (en) 2018-04-30
TW201731875A (zh) 2017-09-16
JP6629437B2 (ja) 2020-01-15
AU2016333511A1 (en) 2018-03-15
TW202210522A (zh) 2022-03-16
HUE049083T2 (hu) 2020-09-28
PH12018500708A1 (en) 2018-10-15
EP3825331A1 (en) 2021-05-26
AU2016333511B2 (en) 2022-11-24
IL257679B (en) 2022-01-01
MA43024B1 (fr) 2020-05-29
EP3356408B1 (en) 2020-03-18
LT3356408T (lt) 2020-06-10
EP3356408A1 (en) 2018-08-08
PL3356408T3 (pl) 2020-08-10
UA125285C2 (uk) 2022-02-16
US11286300B2 (en) 2022-03-29
CO2018002265A2 (es) 2018-05-10
CN108137696A (zh) 2018-06-08
BR112018006579A2 (pt) 2018-10-09
HRP20200767T1 (hr) 2020-07-24
WO2017055541A1 (en) 2017-04-06
DK3356408T3 (da) 2020-05-18
CL2018000728A1 (es) 2019-04-26
SI3356408T1 (sl) 2020-07-31
RU2020124153A (ru) 2020-09-02

Similar Documents

Publication Publication Date Title
IL288457A (en) Humanized anti-human CD19 antibodies and methods of use
HK1250513A1 (zh) 抗ox40抗體及其使用方法
IL257297A (en) Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them
HK1249405A1 (zh) 抗dll3嵌合抗原受體及其使用方法
IL255336A0 (en) Chimeric antigen receptors and methods of using them
HK1259251A1 (zh) 人源化抗c1s抗體及其使用方法
HK1251969A1 (zh) 抗her2抗體和使用方法
IL286208A (en) Monoclonal antibodies of human origin and methods of using them
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
IL284291A (en) Anti-acth antibodies from humans and their use
SI3445785T1 (sl) Humanizirana protitelesa proti CLEVER-1 in njihova uporaba
EP3523333C0 (en) ANTI-CEACAM6 ANTIBODIES AND METHODS OF USE THEREOF